Atypical Hemolytic Uremic Syndrome (aHUS) Latest Advances

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: March 16, 2026

Hematologic disorders in pregnancy: the role of the complement system.

Journal: Expert review of hematology

Published: March 05, 2026

Not So Normal Skin: A Review of the "Random" Skin Biopsy.

Journal: The American Journal of dermatopathology

Published: February 17, 2026

Recurrent Atypical Hemolytic-Uremic Syndrome (aHUS) Associated With CD46 Genetic Mutation: A Report of a Rare Case.

Journal: Cureus

Published: February 12, 2026

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: February 06, 2026

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study).

Journal: Kidney medicine

Published: February 03, 2026

Response to the Letter to the Editor Entitled "Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation".

Journal: Kidney international reports

Published: January 30, 2026

Microangiopathies thrombotiques

Journal: La Revue du praticien

Published: January 23, 2026

Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.

Journal: Pediatric nephrology (Berlin, Germany)

Published: January 16, 2026

Discovery of (3R,4R)-15: An Advanced Factor B Inhibitor Entering Phase 3 for Complement-Mediated Diseases.

Journal: Journal of medicinal chemistry

Published: January 09, 2026

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Journal: Kidney medicine

Published: January 08, 2026

Diagnostic Challenges in Atypical Hemolytic Uremic Syndrome: A Case of Artificial Mitral Valve Dysfunction as a Possible Trigger for Severe Thrombotic Microangiopathy.

Journal: The American journal of case reports

Published: January 08, 2026

Atypical Hemolytic Uremic Syndrome (aHUS) Latest Advances

Find the Latest Research About Atypical Hemolytic Uremic Syndrome (aHUS)

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Hematologic disorders in pregnancy: the role of the complement system.

Hematologic disorders in pregnancy: the role of the complement system.

Not So Normal Skin: A Review of the "Random" Skin Biopsy.

Not So Normal Skin: A Review of the "Random" Skin Biopsy.

Recurrent Atypical Hemolytic-Uremic Syndrome (aHUS) Associated With CD46 Genetic Mutation: A Report of a Rare Case.

Recurrent Atypical Hemolytic-Uremic Syndrome (aHUS) Associated With CD46 Genetic Mutation: A Report of a Rare Case.

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study).

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study).

Response to the Letter to the Editor Entitled "Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation".

Response to the Letter to the Editor Entitled "Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation".

Microangiopathies thrombotiques

Microangiopathies thrombotiques

Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.

Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.

Discovery of (3R,4R)-15: An Advanced Factor B Inhibitor Entering Phase 3 for Complement-Mediated Diseases.

Discovery of (3R,4R)-15: An Advanced Factor B Inhibitor Entering Phase 3 for Complement-Mediated Diseases.

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Diagnostic Challenges in Atypical Hemolytic Uremic Syndrome: A Case of Artificial Mitral Valve Dysfunction as a Possible Trigger for Severe Thrombotic Microangiopathy.

Diagnostic Challenges in Atypical Hemolytic Uremic Syndrome: A Case of Artificial Mitral Valve Dysfunction as a Possible Trigger for Severe Thrombotic Microangiopathy.